Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Shares Issued (2019 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Shares Issued for 7 consecutive years, with $92.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Issued changed N/A year-over-year to $92.4 million, compared with a TTM value of $92.7 million through Sep 2025, up 39003.8%, and an annual FY2024 reading of $294000.0, down 96.63% over the prior year.
  • Shares Issued was $92.4 million for Q3 2025 at X4 Pharmaceuticals, up from $135000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $92.4 million in Q3 2025 and bottomed at $2000.0 in Q3 2023.
  • Average Shares Issued over 5 years is $10.3 million, with a median of $103000.0 recorded in 2021.
  • Peak annual rise in Shares Issued hit 46.84% in 2021, while the deepest fall reached 57.29% in 2021.
  • Year by year, Shares Issued stood at $103000.0 in 2021, then soared by 33.98% to $138000.0 in 2022, then dropped by 29.71% to $97000.0 in 2023, then skyrocketed by 39.18% to $135000.0 in 2024, then soared by 68377.04% to $92.4 million in 2025.
  • Business Quant data shows Shares Issued for XFOR at $92.4 million in Q3 2025, $135000.0 in Q4 2024, and $97000.0 in Q4 2023.